Information

Back Number of 2026

• NEW
  29 May

  Notice of the 70th Ordinary General Meeting of Shareholders

• NEW
  21 May

  Notice of Changes in Officers

• NEW
  21 May

  Notice of Issuance of Class A Preferred Shares through Third-Party Allotment, Partial Amendment of the Articles of Incorporation, and Reduction of Amounts of Share Capital and Legal Capital Surplus

• NEW
  14 May

  FY2025 Supplementary Material of Financial Results

• NEW
  14 May

  Consolidated Financial Results for the Year Ended March 31, 2026(Based on Japanese GAAP)

• NEW
  11 May

  Notice of Recognition of an Impairment Loss, Recognition of a Loss on Valuation of Shares of Subsidiaries and Associates in the Non-consolidated Financial Statements of the Company, and Revisions of Financial Forecasts

• 23 Apr.

  Toward Ensuring a Stable Supply of Off-Patent Medical Products Towa Pharmaceutical Agrees to Collaborate with Sanwa Kagaku Kenkyusho Co., Ltd., with the Aim of Establishing a Backup Production System

• 16 Apr.

  Toward Ensuring a Stable Supply of Off-Patent Medical Products*1 Towa Pharmaceutical Concludes a Basic Agreement with Adragos Pharma Kawagoe on a Contract Manufacturing Partnership for Pharmaceuticals

• 1 Apr.

  Updated IR Calendar

• 1 Apr.

  Updated Corporate Data

• 16 Feb.

  Towa Receives Manufacturing and Marketing Approval for Generic Drugs

• 13 Feb.

  FY2025(3rd quarter) Supplementary Material of Financial Results

• 13 Feb.

  Consolidated Financial Results for the Nine Months Ended December 31, 2025(Based on Japanese GAAP)

• 21 Jan.

  Strategic collaboration between brand-name and generic drug companies Toward Ensuring a Stable Supply of Off-Patent Medicinal Products

• 5 Jan.

  Updated IR Calendar